Geohas Jeff, Daly Anne, Juturu Vijaya, Finch Manley, Komorowski James R
Chicago Research Center, Chicago, Illinois, USA.
Am J Med Sci. 2007 Mar;333(3):145-53. doi: 10.1097/MAJ.0b013e318031b3c9.
The atherogenic index of plasma (AIP), defined as logarithm [log] of the ratio of plasma concentration of triglycerides to high-density lipoprotein (HDL) cholesterol, has recently been proposed as a predictive marker for plasma atherogenicity and is positively correlated with cardiovascular disease risk. The nutrient combination of chromium picolinate and biotin (CPB) has been previously shown to reduce insulin resistance and hyperglycemia in patients with type 2 diabetes (T2DM).
Thirty-six moderately obese subjects with T2DM and with impaired glycemic control were randomized to receive CPB or placebo in addition to their oral hyperglycemic agents for 4 weeks. Measurements of blood lipids (including ratio of triglycerides to HDL cholesterol), fructosamine, glucose, and insulin were taken at baseline and after 4 weeks.
At the final visit, the active group had a significantly lower AIP compared to the placebo group (P < 0.05). A significant difference in triglyceride level (P < 0.02) and the ratio of low-density lipoprotein (LDL) to HDL cholesterol (P < 0.05) was also observed between the groups at the final visit. In the active group, the changes in urinary chromium levels were inversely correlated with the change in AIP (P < 0.05). Urinary chromium levels were significantly increased in the CPB group. In the CPB group, glucose levels decreased at 1 hour and 2 hours and glucose area under the curve and fructosamine level were significantly decreased. Ratios of total to HDL cholesterol, LDL to HDL cholesterol, and non-HDL to HDL cholesterol were significantly decreased between the treatments at final visit. No significant adverse events were observed in the CPB or placebo groups.
These results suggest that the combination of chromium picolinate and biotin may be a valuable nutritional adjuvant therapy to reduce AIP and correlated CVD risk factors in people with T2DM.
血浆致动脉粥样硬化指数（AIP）定义为血浆甘油三酯浓度与高密度脂蛋白（HDL）胆固醇浓度之比的对数，最近被提议作为血浆致动脉粥样硬化性的预测标志物，且与心血管疾病风险呈正相关。先前已表明，吡啶甲酸铬和生物素（CPB）的营养组合可降低2型糖尿病（T2DM）患者的胰岛素抵抗和高血糖。
36名中度肥胖的T2DM患者，血糖控制不佳，除口服降糖药外，随机接受CPB或安慰剂治疗4周。在基线和4周后测量血脂（包括甘油三酯与HDL胆固醇之比）、果糖胺、血糖和胰岛素。
在最后一次随访时，与安慰剂组相比，活性组的AIP显著降低（P < 0.05）。在最后一次随访时，两组之间的甘油三酯水平（P < 0.02）以及低密度脂蛋白（LDL）与HDL胆固醇之比（P < 0.05）也存在显著差异。在活性组中，尿铬水平的变化与AIP的变化呈负相关（P < 0.05）。CPB组的尿铬水平显著升高。在CPB组中，1小时和2小时时血糖水平下降，曲线下血糖面积和果糖胺水平显著降低。在最后一次随访时，治疗之间的总胆固醇与HDL胆固醇之比、LDL与HDL胆固醇之比以及非HDL与HDL胆固醇之比均显著降低。在CPB组或安慰剂组中未观察到显著不良事件。
这些结果表明，吡啶甲酸铬和生物素的组合可能是一种有价值的营养辅助疗法，可降低T2DM患者的AIP及相关的心血管疾病危险因素。
